Characteristics of alloSCT procedure
| Characteristic . | All patients (n = 79) . | CGD (n = 20) . | CID (n = 59) . |
|---|---|---|---|
| Donor | |||
| Matched related | 30 (38%) | 7 (35%) | 23 (39%) |
| Mismatched related | 4 (5%) | 0 | 4 (7%) |
| Mismatched unrelated | 12 (15%) | 3 (15%) | 9 (15%) |
| Matched unrelated | 33 (42%) | 10 (50%) | 23 (39%) |
| Stem cell source | |||
| Bone marrow | 35 (44%) | 13 (65%) | 22 (37%) |
| PBSCs | 44 (56%) | 7 (35%) | 37 (63%) |
| Conditioning intensity | |||
| Full | 33 (42%) | 5 (25%) | 28 (47%) |
| Reduced | 46 (58%) | 15 (75%) | 31 (53%) |
| HCT-CI score | |||
| 0 | 10 (13%) | 1 (5%) | 9 (16%) |
| 1-2 | 44 (56%) | 13 (65%) | 31 (53%) |
| ≥3 | 24 (31%) | 6 (30%) | 18 (31%) |
| Not available | 1 | 0 | 1 |
| Regimen | |||
| Flu/Mel | 19 (24%) | 0 | 19 (32%) |
| Flu/Bu (≤9.6 mg/kg) | 21 (27%) | 15 (75%) | 6 (10%) |
| Flu/Bu (>9.6 mg/kg) | 26 (33%) | 5 (15%) | 21 (36%) |
| Baltimore regimen | 4 (5%) | 0 | 4 (8%) |
| Flu/treosulfan | 2 (3%) | 0 | 2 (3%) |
| Flu/Bu/Thiotepa | 2 (3%) | 0 | 2 (3%) |
| CCP/Bu | 1 (1%) | 0 | 1 (2%) |
| CCP/TBI (12 Gy) | 2 (3%) | 0 | 2 (3%) |
| CCP/Flu | 1 (1%) | 0 | 1 (2%) |
| Flu/TBI (2 Gy) | 1 (1%) | 0 | 1 (2%) |
| In vivo T-cell depletion | |||
| Alemtuzumab | 36 (46%) | 9 (45%) | 27 (46%) |
| Anti-thymocyte globulin | 29 (37%) | 11 (55%) | 18 (31%) |
| GVHD prophylaxis | |||
| Cyclosporine | 75 (95%) | 19 (95%) | 56 (95%) |
| MMF | 56 (71%) | 16 (80%) | 40 (68%) |
| Methotrexate | 15 (19%) | 2 (10%) | 13 (22%) |
| Posttransplant cyclophosphamide | 4 (5%) | 0 | 4 (7%) |
| Characteristic . | All patients (n = 79) . | CGD (n = 20) . | CID (n = 59) . |
|---|---|---|---|
| Donor | |||
| Matched related | 30 (38%) | 7 (35%) | 23 (39%) |
| Mismatched related | 4 (5%) | 0 | 4 (7%) |
| Mismatched unrelated | 12 (15%) | 3 (15%) | 9 (15%) |
| Matched unrelated | 33 (42%) | 10 (50%) | 23 (39%) |
| Stem cell source | |||
| Bone marrow | 35 (44%) | 13 (65%) | 22 (37%) |
| PBSCs | 44 (56%) | 7 (35%) | 37 (63%) |
| Conditioning intensity | |||
| Full | 33 (42%) | 5 (25%) | 28 (47%) |
| Reduced | 46 (58%) | 15 (75%) | 31 (53%) |
| HCT-CI score | |||
| 0 | 10 (13%) | 1 (5%) | 9 (16%) |
| 1-2 | 44 (56%) | 13 (65%) | 31 (53%) |
| ≥3 | 24 (31%) | 6 (30%) | 18 (31%) |
| Not available | 1 | 0 | 1 |
| Regimen | |||
| Flu/Mel | 19 (24%) | 0 | 19 (32%) |
| Flu/Bu (≤9.6 mg/kg) | 21 (27%) | 15 (75%) | 6 (10%) |
| Flu/Bu (>9.6 mg/kg) | 26 (33%) | 5 (15%) | 21 (36%) |
| Baltimore regimen | 4 (5%) | 0 | 4 (8%) |
| Flu/treosulfan | 2 (3%) | 0 | 2 (3%) |
| Flu/Bu/Thiotepa | 2 (3%) | 0 | 2 (3%) |
| CCP/Bu | 1 (1%) | 0 | 1 (2%) |
| CCP/TBI (12 Gy) | 2 (3%) | 0 | 2 (3%) |
| CCP/Flu | 1 (1%) | 0 | 1 (2%) |
| Flu/TBI (2 Gy) | 1 (1%) | 0 | 1 (2%) |
| In vivo T-cell depletion | |||
| Alemtuzumab | 36 (46%) | 9 (45%) | 27 (46%) |
| Anti-thymocyte globulin | 29 (37%) | 11 (55%) | 18 (31%) |
| GVHD prophylaxis | |||
| Cyclosporine | 75 (95%) | 19 (95%) | 56 (95%) |
| MMF | 56 (71%) | 16 (80%) | 40 (68%) |
| Methotrexate | 15 (19%) | 2 (10%) | 13 (22%) |
| Posttransplant cyclophosphamide | 4 (5%) | 0 | 4 (7%) |
Bu, busulfan; CCP, cyclophosphamide; Flu, fludarabine; Mel, melphalan; MMF, mycophenolate mofetil; PBSC, peripheral blood stem cell; TBI, total body irradiation.